114 related articles for article (PubMed ID: 32338509)
41. Generating thermostabilized agonist-bound GPR40/FFAR1 using virus-like particles and a label-free binding assay.
Hirozane Y; Motoyaji T; Maru T; Okada K; Tarui N
Mol Membr Biol; 2014 Aug; 31(5):168-75. PubMed ID: 25068810
[TBL] [Abstract][Full Text] [Related]
42. Extracellular Loop 2 of the Adenosine A1 Receptor Has a Key Role in Orthosteric Ligand Affinity and Agonist Efficacy.
Nguyen AT; Baltos JA; Thomas T; Nguyen TD; Muñoz LL; Gregory KJ; White PJ; Sexton PM; Christopoulos A; May LT
Mol Pharmacol; 2016 Dec; 90(6):703-714. PubMed ID: 27683014
[TBL] [Abstract][Full Text] [Related]
43. Graded activation and free energy landscapes of a muscarinic G-protein-coupled receptor.
Miao Y; McCammon JA
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12162-12167. PubMed ID: 27791003
[TBL] [Abstract][Full Text] [Related]
44. Docking and MD study of histamine H4R based on the crystal structure of H1R.
Feng Z; Hou T; Li Y
J Mol Graph Model; 2013 Feb; 39():1-12. PubMed ID: 23220277
[TBL] [Abstract][Full Text] [Related]
45. Does the Lipid Bilayer Orchestrate Access and Binding of Ligands to Transmembrane Orthosteric/Allosteric Sites of G Protein-Coupled Receptors?
Szlenk CT; Gc JB; Natesan S
Mol Pharmacol; 2019 Nov; 96(5):527-541. PubMed ID: 30967440
[TBL] [Abstract][Full Text] [Related]
46. Activation Mechanism of Corticotrophin Releasing Factor Receptor Type 1 Elucidated Using Molecular Dynamics Simulations.
Uba AI; Scorese N; Dean E; Liu H; Wu C
ACS Chem Neurosci; 2021 May; 12(9):1674-1687. PubMed ID: 33860667
[TBL] [Abstract][Full Text] [Related]
47. Conserved Residues Control the T1R3-Specific Allosteric Signaling Pathway of the Mammalian Sweet-Taste Receptor.
Chéron JB; Soohoo A; Wang Y; Golebiowski J; Antonczak S; Jiang P; Fiorucci S
Chem Senses; 2019 May; 44(5):303-310. PubMed ID: 30893427
[TBL] [Abstract][Full Text] [Related]
48. Point mutation of Ffar1 abrogates fatty acid-dependent insulin secretion, but protects against HFD-induced glucose intolerance.
Sabrautzki S; Kaiser G; Przemeck GKH; Gerst F; Lorza-Gil E; Panse M; Sartorius T; Hoene M; Marschall S; Häring HU; Hrabě de Angelis M; Ullrich S
Mol Metab; 2017 Oct; 6(10):1304-1312. PubMed ID: 29031729
[TBL] [Abstract][Full Text] [Related]
49. [The role of brain n-3 fatty acids-GPR40/FFAR1 signaling in pain].
Nakamoto K; Tokuyama S
Nihon Yakurigaku Zasshi; 2018; 151(1):21-26. PubMed ID: 29321392
[TBL] [Abstract][Full Text] [Related]
50. Molecular dynamics simulations on RORγt: insights into its functional agonism and inverse agonism.
Yuan CM; Chen HH; Sun NN; Ma XJ; Xu J; Fu W
Acta Pharmacol Sin; 2019 Nov; 40(11):1480-1489. PubMed ID: 31316175
[TBL] [Abstract][Full Text] [Related]
51. Molecular modeling study on the dynamical structural features of human smoothened receptor and binding mechanism of antagonist LY2940680 by metadynamics simulation and free energy calculation.
Bai Q; Shen Y; Jin N; Liu H; Yao X
Biochim Biophys Acta; 2014 Jul; 1840(7):2128-38. PubMed ID: 24637074
[TBL] [Abstract][Full Text] [Related]
52. Structural basis for GPCR signaling by small polar versus large lipid metabolites-discovery of non-metabolite ligands.
Lückmann M; Trauelsen M; Frimurer TM; Schwartz TW
Curr Opin Cell Biol; 2020 Apr; 63():38-48. PubMed ID: 31951921
[TBL] [Abstract][Full Text] [Related]
53. A novel antidiabetic therapy: free fatty acid receptors as potential drug target.
Sekiguchi H; Kasubuchi M; Hasegawa S; Pelisch N; Kimura I; Ichimura A
Curr Diabetes Rev; 2015; 11(2):107-15. PubMed ID: 25732031
[TBL] [Abstract][Full Text] [Related]
54. Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes.
Winters MP; Sui Z; Wall M; Wang Y; Gunnet J; Leonard J; Hua H; Yan W; Suckow A; Bell A; Clapper W; Jenkinson C; Haug P; Koudriakova T; Huebert N; Murray WV
Bioorg Med Chem Lett; 2018 Mar; 28(5):841-846. PubMed ID: 29456108
[TBL] [Abstract][Full Text] [Related]
55. Lack of GPR40/FFAR1 does not induce diabetes even under insulin resistance condition.
Matsuda-Nagasumi K; Takami-Esaki R; Iwachidow K; Yasuhara Y; Tanaka H; Ogi K; Nakata M; Yano T; Hinuma S; Taketomi S; Odaka H; Kaisho Y
Diabetes Obes Metab; 2013 Jun; 15(6):538-45. PubMed ID: 23331570
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and Characterization of a Promising Novel FFAR1/GPR40 Targeting Fluorescent Probe for β-Cell Imaging.
Bertrand R; Wolf A; Ivashchenko Y; Löhn M; Schäfer M; Brönstrup M; Gotthardt M; Derdau V; Plettenburg O
ACS Chem Biol; 2016 Jun; 11(6):1745-54. PubMed ID: 27115176
[TBL] [Abstract][Full Text] [Related]
57. Bornyl-Containing Derivatives of Benzyloxyphenylpropanoic Acid as FFAR1 Agonists: In Vitro and In Vivo Studies.
Pon'kina DA; Kuranov SO; Marenina MK; Meshkova YV; Zhukova NA; Khvostov MV; Luzina OA; Tolstikova TG; Salakhutdinov NF
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376118
[TBL] [Abstract][Full Text] [Related]
58. FFAR4 Is Involved in Regulation of Neurotensin Release From Neuroendocrine Cells and Male C57BL/6 Mice.
Li J; Song J; Li X; Rock SB; Sinner HF; Weiss HL; Weiss T; Townsend CM; Gao T; Evers BM
Endocrinology; 2018 Aug; 159(8):2939-2952. PubMed ID: 29796668
[TBL] [Abstract][Full Text] [Related]
59. Structural complexes of the agonist, inverse agonist and antagonist bound C5a receptor: insights into pharmacology and signaling.
Rana S; Sahoo AR; Majhi BK
Mol Biosyst; 2016 Apr; 12(5):1586-99. PubMed ID: 26978009
[TBL] [Abstract][Full Text] [Related]
60. Activation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) by free fatty acid receptor 1 (FFAR1/GPR40) protects from palmitate-induced beta cell death, but plays no role in insulin secretion.
Panse M; Gerst F; Kaiser G; Teutsch CA; Dölker R; Wagner R; Häring HU; Ullrich S
Cell Physiol Biochem; 2015; 35(4):1537-45. PubMed ID: 25792236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
